WO2005099789A1 - Traitement de la sepsie - Google Patents

Traitement de la sepsie Download PDF

Info

Publication number
WO2005099789A1
WO2005099789A1 PCT/GB2005/001501 GB2005001501W WO2005099789A1 WO 2005099789 A1 WO2005099789 A1 WO 2005099789A1 GB 2005001501 W GB2005001501 W GB 2005001501W WO 2005099789 A1 WO2005099789 A1 WO 2005099789A1
Authority
WO
WIPO (PCT)
Prior art keywords
resin
channel
carbon
blood
plasma
Prior art date
Application number
PCT/GB2005/001501
Other languages
English (en)
Inventor
Stephen Robert Tennison
Gary James Phillips
Sergey Victorovich Mikhalovsky
Andrew William Lloyd
James Macniven Courtney
Original Assignee
Mast Carbon International Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mast Carbon International Limited filed Critical Mast Carbon International Limited
Publication of WO2005099789A1 publication Critical patent/WO2005099789A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3475—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate with filtrate treatment agent in the same enclosure as the membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption

Definitions

  • the present invention relates to a novel device for the treatment of inflammatory conditions particularly sepsis and its sequalae and to materials for use in that device.
  • Sepsis is a major cause of morbidity and mortality in intensive care units, not only within the UK but also throughout the world. As many as 30,000 cases of sepsis occur each year in the UK alone with mortality rates being particularly high for those patients developing multi-organ dysfunction syndrome (MODS).
  • MODS multi-organ dysfunction syndrome
  • Human sepsis can be initiated by the presence of endotoxin or exotoxin from microorganisms, parasites, exogenous substances including chemical agents, drug overdose and snake toxins or can be a consequence of trauma.
  • Endotoxin is a constituent of the outer cell membrane of gram negative bacteria and via a series of events the endotoxin stimulates the release of a number of inflammatory mediators including cytokines and activation products 1 .
  • Exotoxins are released from the gram positive bacterial cell upon cleavage of a single peptide. They can act as potent pyrogens and superantigens, stimulating the expansion of host T cell populations and related inflammatory mediators independent of antigenic specificity. When released, these inflammatory species evoke a systemic inflammatory response, which may result in septic shock, organ failure, multiple organ dysfunction syndrome (MODS) and death. Gram negative sepsis accounts for between 50-60% of cases of sepsis while gram positive sepsis is responsible for 35-40% of reported cases. The remaining cases are the result of fungal, viral or protozoan insult 2 .
  • Compensatoiy anti-inflammatory reaction may also be important in the pathogenesis of sepsis with the release of inappropriate amounts of anti-inflammatory mediators such as IL-4, IL-10, IL-11, IL- 13, IL-1 receptor agonist and soluble TNF-alpha receptors 3 .
  • anti-inflammatory mediators such as IL-4, IL-10, IL-11, IL- 13, IL-1 receptor agonist and soluble TNF-alpha receptors 3 .
  • IL-4, IL-10, IL-11, IL- 13, IL-1 receptor agonist and soluble TNF-alpha receptors 3 To counteract the process of sepsis it is necessary to reduce the systemic level of both endotoxin and exotoxin and the circulating pro and anti-inflammatory mediators.
  • Multiple organ dysfunction syndrome represents the main cause of death in surgical intensive care units with approximately 90% mortality occurring when three or more organs fail.
  • MODS can be divided into primary and secondary MODS depending on the time to manifestation and the associated pathophysiological events
  • Secondary MODS develops as a consequence of the host response to various stimuli rather than the original insult itself.
  • secondary MODS generally occurs between day 4 and 14 following the initial trauma event and is based on the systemic inflammatory response (SIRS).
  • SIRS systemic inflammatory response
  • This inflammatory response is a result of the uncontrolled synthesis and release of pro-inflammatory cytokines such as TNF- ⁇ and, IL-l ⁇ , IL-6 and IL-8 by the activation and continuous stimulation of tissue macrophages and monocytes.
  • This process is tenned cytokinemia and is a result of bacteremia and/or exo/endotoxemia following bacterial invasion of the host either early after injury, through compromised skin barriers or via bacterial translocation (e.g. from the gut), or in the late post-traumatic period during infectious episodes.
  • inflammation is a localised event that acts to contain and eradicate infecting organisms or to cleanse damaged tissue of cell debris. Uncontrolled inflammation, however, can become detrimental with the destruction of local tissues with eventual major tissue damage if the process continues unchecked.
  • the pro-inflammatory response can become more widespread with the activation of multiple effector cells and humoral protein cascades such as that in the coagulation and complement systems.
  • the intravascular response may lead to more widespread damage of the vascular endothelial system, which, in turn, potentiates distant organ failure.
  • systemic inflammation becomes self perpetuating due to the continued release of locally or systemically produced pro-inflammatory mediators into the circulation.
  • TNF- ⁇ acting synergistically with other cytokines such as IL-l ⁇ and IFN- ⁇
  • IL-l ⁇ cytokines
  • IFN- ⁇ cytokines
  • TNF- ⁇ or IL-l ⁇ e.g. anti-TNF antibodies, IL- l ⁇ receptor agonist and IL-10
  • these trials have failed to demonstrate any significant therapeutic benefit ,5 ' ' 7 ' 8 ' ' ' (1"8 ' ) .
  • monoclonal antibodies against endotoxin has proved unconvincing as they are only believed to bind to a specific endotoxin and are, therefore, ineffective against endotoxin derived from other bacterial strains.
  • a more promising extracorporeal strategy for the treatment of sepsis is the use of plasma exchange to remove high molecular weight cytokines and endotoxins.
  • plasmapheresis may be useful to control the progress of sepsis 16 ' 17,18 ⁇ - l3 5
  • This process involves filtering blood through membranes with a high molecular weight cut-off ( ⁇ 100kD) to separate a patient's cells from their plasma which may then be exchanged for healthy donor plasma.
  • ⁇ 100kD high molecular weight cut-off
  • activated carbons from natural sources and amberlites have been known to have adsorbent properties and have been studied in relation to the development of extracorporeal bioartificial liver devices.
  • Such adsorbents have been demonstrated to adsorb IL-l ⁇ , IL-6 and TNF- ⁇ although with limited efficiency 23 ' 24 ' 25 ' 26 ' 27 (20"24 Indeed, Hughes and co-workers have completed a clinical study 28 ' 29 ( - 25 ' 6) of existing medical haemoperfusion adsorbents and have highlighted a number of important findings.
  • the extraco ⁇ oreal circulation consisted of plasma filtration followed by the passage of the plasma filtrate through a hydrophobic sorbent and reinfusion into the venous line.
  • This system employed a non-selective hydrophobic resin as the stationary adsorbent phase.
  • the non-selectivity of the adsorbent used will clearly limit the efficiency of such a system.
  • an efficient and cost effective extraco ⁇ oreal device for the treatment of sepsis which includes a separation system to separate the blood cells from plasma, combined with an effective adsorbent system for the removal of the inflammatory mediators including cytokines and endo/exotoxins and which would then allow the two streams to be recombined and passed directly back to the body eliminating the requirement for replacement plasma.
  • a separation system to separate the blood cells from plasma
  • an effective adsorbent system for the removal of the inflammatory mediators including cytokines and endo/exotoxins and which would then allow the two streams to be recombined and passed directly back to the body eliminating the requirement for replacement plasma.
  • the materials used do not cause either a further immune response, or excessive platelet activation (blood coagulation) on the feed side of the filter.
  • a method for the treatment of blood which comprises (1) passing the blood through a monolithic porous carbon structure, (2) allowing the plasma components to pass through the walls of the monolith to form two streams, a plasma permeate stream passing through the walls of the monolith and a retentate stream containing the majority of the blood cells, (3) adsorbing the contrary substances from the plasma permeate stream in the walls of the monolith and (4) combining the filtrate stream and the retentate stream.
  • the combined stream can be passed back into a body from where the blood was taken.
  • the invention also provides apparatus for treating blood which comprises (i) a porous monolithic carbon having at least one channel formed in it (ii) an inlet for the blood stream to enter the channel whereby blood passes down the channel and passes through the walls of the channel to form two streams, a filtrate stream and retentate stream (iii) means to combine the retentate and filtrate stream and (iv) an outlet for the combined stream.
  • an inlet channel which is the retentate channel and a filtrate channel into which the filtrate enters after passing through the walls of the inlet channel; the filtrate channel is connected to the outlet.
  • the contrary substances which can be removed from the blood include endotoxins and exotoxins and the circulating pro and anti-inflammatory mediators e.g.IL-l ⁇ , IL- 6, TNF ⁇ , IL-4, IL-10, IL-11, IL-13, IL-1 receptor agonist, soluble TNF-alpha receptors and LPS.
  • porous carbon is in a single piece i.e. not granular or not composed of granular carbons bound together by a binder etc.
  • the monolithic carbon additionally contains large transport channels through which the feed /retentate steam flows and by which means the pressure drop in the device can be controlled.
  • the monolithic carbon has a continuous channel structure.
  • the continuous channel structure is defined by the channel dimension, W, and the wall thickness, t, or for an asymmetric monolith (figure 4) by R and F as well as t where R and F are dimensions of the feed (F) and retentate (R) channels.
  • the walls of the monolithic carbon have a macroporous structure.
  • macroporeous is meant that the carbon has continuous voids or pores through which liquid, specifically blood plasma, can pass from the feed to the retentate with a mean pore size of greater than 500mn.
  • the macropore structure in the wall of the monolith is controlled by the particles used to form the monolith.
  • the macropore size is typically 20% of the size of the precursor resin particle. This can be varied over a wide range from a maximum particle size of approximately 10% of the wall thickness, t, to a minimum practical particle size of around 10 microns. This gives a macropore size within the wall for a 1mm wall thickness between approximately 2 and 20 microns.
  • the pore size fixes the filtration characteristics of the wall which is required to filter blood cells from the whole blood and to allow plasma containing middle molecular weight proteins to pass through. There is an optimum particle size that will maximise the permeability of the wall whilst minimising the passage of blood cells. As the retentate and filtrate streams are ultimately recombined it is not essential that 100% of the blood cells are removed from the filtrate but a high separation is beneficial.
  • the maximum liquid flow through the wall for a given pressure differential or flow linear velocity is defined by the Blake-Kozeny equation:-
  • the carbon particles making up the walls of the monolith contain micro ( ⁇ 2nm) meso (2-50nm) and small macropores (50-200nm) suitable for the adso ⁇ tion of small, middle and high molecular weight molecules with a mean pore size between 0.5 and 200nm.
  • the monoliths are either tubular with a central channel of between 1 and 10mm and a wall thickness of between 0.2 and 2mm or are rectangular channel monoliths with a cell structure (cells per square cm -cpcm) where the channel size is between 100 and 2000 microns and the wall thickness is between 100 and 2000 microns and with an open area of between 30 and 60% to give a good carbon packing density per unit volume and acceptable mass transfer characteristics.
  • the cell structure should be asymmetric to provide control over the flow and pressure drop in the feed and filtrate channels. It is also required that the filtrate channels be closed off at the monolith inlet.
  • the monoliths can be produced in lengths from around 1mm to 200cm but for use in the present invention this will depend on the use.
  • the monolithic porous carbon can be made by partially curing a phenolic resin to a solid, comminuting the partially cured resin, extruding the comminuted resin, sintering the extruded resin so as to produce a form-stable sintered product and carbonising and activating the form-stable sintered product.
  • EP 0 254 551 gives details of methods of forming the porous carbons suitable for forming the porous carbon used in the present invention and its contents are included herein by reference.
  • the process comprises (a) partially curing a phenolic resin to a solid, (b) grinding the solid to form particles, (c) forming the resulting ground product into a dough and extruding at a pressure in the range 0 to 20 MPa, (d) sintering the shaped solid so as to produce a form-stable sintered product.
  • the sintered product can then be carbonised and activated.
  • PCT/GB02/01142 gives details of producing monolithic structures using the sintered resin structures of EP 0 254 551 and this is included herein by reference.
  • Phenolic resins are well known materials. They are made by the reaction of a phenol and an aldehyde, e.g. formaldehyde. The condensation is initially carried out to produce a partially condensed product. The condensation may be carried out so as to produce a resin which is fully curable on further heating. Alternatively the condensation may be carried out so as to produce a novolak resin which is only curable when an additional cross-linking agent is mixed with it e.g. hexamethylene tetramine (known as "hexamine” or "hex”). It is preferred to use hexamine-cured novolak resins in the process of the present invention.
  • the resin cure should be controlled so that it is sufficient to prevent the resin melting during subsequent carbonisation but low enough so that the particles produced during the milling step can sinter during subsequent processing.
  • the temperature and duration of the partial curing step is selected as to give a degree of cure sufficient to give a sinterable product, and being such that a sample of the partially cured solid when ground to produce particles in the size range 106-250 microns and tabletted in a tabletting machine gives a pellet with a crush strength which is not less than 1 N/mm.
  • the pellet after carbonisation has a crush strength of not less than 8 N/mm.
  • sintering we mean a step which causes the individual particles of phenolic resin to adhere together without the need for a separately introduced binder, while retaining their individual identity to a substantial extent on heating to carbonisation temperatures.
  • the particles must not melt after forming so as to produce a molten mass of resin, as this would eliminate the internal open porosity of the article.
  • the open porosity (as opposed to the closed cells found in certain types of polymer foams) is believed to be important in enabling formed articles to retain their shape on carbonisation.
  • the comminuted resin particles have a particle size of 1 to 250 microns, more preferably from 10 to 100 microns.
  • the resin powder size is between around 20 microns and 75 microns which provides for a macropore size of between 4 and 15 microns with a macropore volume of around 40%.
  • the size of the resin is selected so as to give an optimum balance between the permeation rate of the plasma component through the filter and the separation of the blood cells from the plasma.
  • the milled powder can then be extruded to produce polymeric monolithic structures with a wide range of cell structures, limited only by the ability to produce the required extrusion die and suitable dies are available commercially.
  • the monolith has a bimodal structure - the visible channel structure with either the central channel in a simple tube or the open cells in a square channel monolith of around 100 to 2000 microns cell dimension and cell walls with thickness between around 100 and 2000 microns - and the macropore structure within the walls generated by the sintered resin particles.
  • the carbonisation steps take place preferably by heating above 600°C for the requisite time e.g. 1 to 48 hours and takes place under an inert atmosphere or vacuum to prevent oxidation of the carbon.
  • the material loses around 50% weight and shrinks by around 50% volume but, provided the resin cure stage was correctly carried out, this shrinkage is accommodated with no distortion of the monolith leading to a physical structure identical to that of the resin precursor but with dimensions reduced by approx 30%.
  • the macropore size is also reduced by ⁇ 30% although the macropore volume (ml/ml) remains unaltered.
  • the microstructure of the porous carbon develops. After carbonisation the monolith behaves as a molecular sieve due to partial blocking of the microstructure by the decomposition products from the carbonisation process. These blockages must be removed to provide rapid access to the internal structure of the carbon that is essential for the operation of the monoliths as adso ⁇ tion devices.
  • microporous pores within the carbon particles suitable for the adso ⁇ tion of low molecular weight molecules with a mean pore size of less than 2nm.
  • pores within the carbon matrix suitable for the adsorption of middle molecular weight molecules with a mean pore size of between 2 and 50nm.
  • macroporous is meant pores within the carbon particles suitable for the adso ⁇ tion of larger protein bound molecules of greater than 50nm.
  • micro and mesoporosity of the walls of the monolithic structures fix the adso ⁇ tion characteristics of the carbon for the various materials that are to be removed from the plasma filtrate.
  • the micropores are responsible for the removal of small molecules such as billirubin. Efficient removal of these molecules requires pores in the range of 0.5 to 2nm. These are generated from the resin matrix material and also partly from the secondary additive carbon.
  • the monolithic porous carbon can be activated to provide the necessary micropore volume and surface area.
  • Activation can take place in either steam or carbon dioxide at temperatures above approximately 700°C and 800°C respectively or in combinations of these gases.
  • the activation process is carried out for a time that varies with the temperature and the activation gas composition, such that a carbon weight loss of between 20 and 40% is achieved.
  • the activation is carried in CO 2 at 850 to 1000°C.
  • Patent application WO 02/12380 A2 discloses a means for producing bead form phenolic resin derived carbons with a bimodal pore structure comprising micropores and meso/macropores using a solvent pore forming route and this patent is included herein by reference.
  • these materials cannot be formed directly into monolithic structures as the high degree of cure required to generate the meso/macro pores prevents the resin particles from sintering.
  • Patent application PCT/GB01/03560 discloses a method for the production of a meso/macroporous monolithic carbon by using a meso/macroporous phenolic resin, produced according to patent WO 02/12380 A2, in conjunction with novolak phenolic resin as a binder and this application is inco ⁇ orated herein by reference. If the meso/macroporous resin powder is mixed with a powder comprising thermoplastic novolak and hexamine curing agent, and tins is then extruded using methocell as an extrusion agent, the material can be dried, carbonised and activated to give a bimodal micro plus meso/macroporous carbon monolithic structure.
  • the drawbacks to this route are that the novolak resin binder tends to partially infill the meso/macro pore structure of the cured resin component leading to a reduction in pore volume and the mesopore size of the cured resin in the l-5nm pore size range.
  • Patent publication WO 2004/087612 discloses a method for the production of monolithic structures comprising mixtures of the sintered phenolic resin, produced according to patent EP 0 254 551, with other materials such as powdered activated carbons and this is included herein by reference. According to this method it is possible to produce a monolithic structure using the partially cured resin powders of EP 0 254 551, and the monolithic structures of PCT/GB02/01142 producing channel structures where the walls comprise a mixture of micropores, derived from the resin component, and controlled structure meso/macro pores derived from the secondary activated carbon or other porous material component.
  • the binary route of WO 2004/087612 can also be used with mixtures of the sinterable phenolic resin powder according to EP 0254551 and the meso/macro porous resin beads of WO 02/12380 A2.
  • the carbon formed comprises the micropores from the sinterable resin component and the bead form resin combined with the meso/macro pores derived from the bead form resin.
  • This method has the advantage that it can be used with much higher loadings of the mesoporous beads than is possible with the mesoporous powdered activated carbons.
  • the carbon monoliths have a surface area of at least 600m2/g, preferably in excess of 1000m2/g with a controlled distribution of micro, meso and macro pores.
  • the adso ⁇ tion of cytokines, endotoxins, exotoxins and other smaller toxic molecules is also influenced by the surface chemistry of the adsorbent matrix.
  • the phenolic resin derived carbons of this invention provide a unique degree of control over this where the surface oxygen functionality can be controlled over wide ranges through controlled activation processes using gas phase or liquid phase oxidation processes, including approaches such as electrochemical oxidation.
  • the invention combines the filtration properties of a novel 3 -dimensional monolithic carbon matrix with the adso ⁇ tive potential of novel pyrolysed carbons produced with defined porosity.
  • Phenolic resin derived mesoporous carbon beads 31 have been demonstrated to have extremely high biocompatibility due to their high mechanical strength, which reduces the formation of 'fines,' and absence of toxic leachables. This biocompatibility allows them to be used uncoated, and so display much faster adso ⁇ tion kinetics when compared to their nearest coated equivalents.
  • Other polymer-based pyrolysed carbons have previously been used in the former USSR for haemoperfusing patients with acute poisoning 32 .
  • the apparatus is used for the control of sepsis by:- a) first filtering the blood stream to partially separate the blood cells from the plasma, b) removing the inflammatory mediators including cytokines, endotoxins, exotoxins and other toxic components from the plasma component within the walls of the filter devices, c) re-combining the cleaned plasma permeate and the partially separated retentate stream containing the blood cells, d) re-injecting the combined stream back into the patient.
  • Fig. 1 shows the principle of the invention schematically
  • Fig. 2 shows one embodiment using a plurality of tubes
  • Fig. 3 shows an embodiment using a carbon monolith
  • Fig. 4 shows an embodiment with rectangular channels
  • Fig. 5 shows the dimensions of the structure of fig. 4
  • Fig. 6 shows the macroporous carbon wells for small scale in-vitro testing
  • Fig 7 shows the pore structure of the mesoporous activated carbons
  • mesoporous resin bead mesoporous resin bead
  • Figs. 8 to 13 show the results of the examples.
  • the device comprises a tube formed of a porous monolithic carbon formed by the method of example 1 of Patent application number WO 2004/087612 with a feed channel (2) passing through walls (4).
  • the whole blood (1) enters the feed channel (2) at one end of the device.
  • the filtrate (7) comprising essentially plasma, passes through the channel wall (4) into a parallel channel and is cleaned of endotoxins and cytokines by adso ⁇ tion within the wall.
  • the retentate (5) comprising a blood cell concentrate leaves the channel exit.
  • the filtrate (3) and retentate (5) streams are recombined (6) and returned to the venous blood and systemic circulation.
  • this shows a multi-tubular device which comprises monolithic carbon tubes (11) (made as in fig. 1) with walls (20) and inlet channels (19) mounted in a reactor (14) with feed (21) and retentate (13) collection chambers.
  • the filtrate passes through the walls of the tubes and is collected in the body of the reactor leaving as stream (8) via the retentate pressure controller (9).
  • the control of the pressure drop can be achieved by the external pressure control devices (18) and (9) in the retentate (16) and filtrate (8) streams respectively.
  • the feed and permeate linear velocities are controlled by the free volume on the feed and permeate sides of the tube, the feed velocity and the permeation rate.
  • the retentate and filtrate streams are recombined in stream (10) and returned to the venous system.
  • the channels are formed in a porous synthetic carbon monolith as shown in figures 3 and 4 where the filtration surface area as a function of the device volume can be maximised.
  • This can either comprise multiple round channels as shown in figure 3 or, preferably, square or rectangular channels as shown in figure 4.
  • this structure is shown in side view in fig. 4a and end view in fig. 4b.
  • the smaller feed channels (22) pass directly through the monolith. These channels are made sufficiently small that the high linear velocity both reduces deposit formation on the walls and maintains sufficient pressure drop along the channel to force the filtrate through the monolith walls (23) into the filtrate collection channels (26).
  • the filtrate channels are blocked at the blood inlet end of the device (25) to ensure that all the incoming blood passes through the feed channels.
  • the filtrate channels are sized so that there is negligible pressure drop in the filtrate flow.
  • fig. 5 shows the macroporous channel structure which is defined by the channel dimension, W, and the wall thickness, t, or for an asymmetric monolith as shown in figure 3 by R and F as well as t. As described above these fix the ratio of open to closed area and therefore the flow velocities along the tube. This pore size then fixes the permeability of the wall and the maximum liquid flow through the wall form a given pressure differential or flow linear velocity as defined by the Blake-Kozeny equation:-
  • Moulded carbon forms were made using the apparatus of fig. 6 in which there is a Perspex (RTM) holder (31) in which is placed a carbon well (32) made from the' sintered phenolic resin used to produce the monolith carbons.
  • RTM Perspex
  • the macro, micro and meso porous structure of the carbon well could be controlled to be identical to that of the channel monoliths described in figures 1 to 5.
  • Figure 7 shows the pore structures of the carbons used in the production of the binary materials. These comprise the commercially available mesoporous carbon powders supplied by CECA (CXN) and PICA (EPII and SC10). The EPII was also available in two particle sizes, 8-15microns and 15-30 microns, although this had no impact on the pore structure.
  • the resin derived carbons comprise the carbon from the mesoporous resin beads, prepared according to WO 025/12380 A2, and the sinterable, non porous resin prepared according to EP0254551 that forms the underlying structure. It can be seen that the pore size increases in the order:- Microporous resin ⁇ EPII ⁇ SC10 ⁇ CXN ⁇ mesoporous resin beads
  • the following example demonstrates the structures that can be produced through the use of the binary combinations of the non porous resin with either the commercial carbons or the mesoporous resin beads.
  • the amount of commercial activated carbon powder that can be inco ⁇ orated into the wells is limited by the shrinkage of the resin matrix.
  • the wells can be produced using up to 100%) of the mesoporous beads.
  • the formulations used are summarised in the table 1 :-
  • the formulation is parts microporous resin/parts mesoporous resin.
  • the pore structures of these binary wells are shown in figure 7. Whilst the binary resin structures can be produced with ratios varying between 100% of each component the amount of carbon that can be inco ⁇ orated is limited to approximately 30%) volume.
  • LPS molecular mass varies. Subunits are 10-20kDa, but aggregate into complexes with plasma proteins. Complex molecular mass ranges from 100-lOOOkDa. TNF (17kDa) forms dimers and trimers and has a molecular size of approximately 51 kDa. In plasma IL-6 (21-28kDa) can complex with the carrier protein Alpha2M to give 42-45kDa, IL-l ⁇ has a size of 17kDa, and IL-8 is the smallest at around 8kDa.
  • Example 2 Use of Carbon powders and Carbon wells to remove FITC-labelled LPS from plasma
  • Fluorescein-isothiocyanate labelled-lipopolysaccharide (FITC-LPS, Sigma) was dissolved in phosphate-buffered saline (PBS) with 10% human plasma (NBS) to give a concentration of lO ⁇ g/ml.
  • the FITC-LPS adso ⁇ tion profile for the carbonized powders 1-14 is displayed in Figure 8.
  • Carbon powder 1 & 5 displayed efficient removal of FITC-LPS from plasma, along with the carbon powder activation range 11-14.
  • the ability of the binarycarbon wells to remove FITC-LPS from human plasma is presented in Figure 9.
  • the pattern of LPS removal was similar to that found for the equivalent powder adso ⁇ tion of FITC-LPS (Fig 8). Saturation effects may have increased measurable LPS present in solution at the two later time points.
  • Carbon wells C, D and E displayed superior adso ⁇ tion capacity when compared to microporous well A, and to the Adsorba 300C control, particularly at the first time point.
  • Table 2 The FITC-LPS adso ⁇ tion profile for the carbonized powders 1-14 is displayed in Figure 8.
  • Carbon powder 1 & 5
  • Example 3 Use of Carbon powders to remove TNF, IL-6, IL-8 and IL-l ⁇ from plasma
  • Fresh frozen human plasma was defrosted and spiked with the recombinant human cytokines; TNF, IL-6, IL-8 and IL-l ⁇ (BD Biosciences) at a concentration of 1000, 2000, 500 and 1000 pg/ml respectively.
  • Controls consisted of spiked plasma, or plasma only with no adsorbent present, and Adsorba 300C (Norit RBX cellulose coated carbon, Gambro). Materials were incubated at 37 °C while shaking (90 rpm).
  • samples were centrifuged (125 g) and the supernatant collected and stored at -20 °C prior to ELIS A analysis for the presence of cytokines.
  • Samples were diluted 1 :4 (TNF, IL-8), 1:10 (IL-6) and 1 :2 (IL- 1 ⁇ ) in assay diluent prior to analysis.
  • the four cytokine adso ⁇ tion profiles for the carbon powders 1-14 are displayed in Figures lOa-d.
  • the most mesoporous Carbon powder 5 displayed efficient removal of all four cytokines, whilst the mesoporous carbon powder 3 also exhibited significant removal of IL-6, IL-8 and IL-l ⁇ .
  • the more microporous carbon powders 1 & 2 removed significantly less of the two larger cytokines TNF and IL-6. It can clearly be seen from Figure 10a, that as the degree of activation increases in the adsorbent range 9-14, removal of TNF the largest of the cytokines examined increased accordingly from 70-97%).
  • Activation increases the number of micropores within the structure of the carbon at the larger end of the micropore range ( ⁇ 0.2nm) and clearly results in greater uptake.
  • This micropore size range may be critical for the cytokine size range (21-51 kDa) of interest in this study, and goes some way to reinforcing the relationship between pore size and adso ⁇ tion capacity when the adsorbant is at a critical molecular weight. It is important to note, however, that activation in air or carbon dioxide alters the functional groups present at the surface of the carbon and thereby may influence the degree of adso ⁇ tion.
  • Example 4 Use of Carbon wells to remove TNF, IL-6, IL-8 and IL-l ⁇ from plasma
  • Fresh frozen human plasma (NBS) was defrosted and spiked with the recombinant human cytokines; TNF, IL-6 & IL-8 (BD Biosciences) at a concentration of 1000, 2000 and 500 pg/ml respectively.
  • Spiked plasma (1.8 ml) was added to the surface of the binary carbon wells and tissue culture plastic controls and incubated at 37 °C (21 hours). Plasma filtrate that had passed through the carbon matrix was collected and tested by ELISA for the presence of cytokines. Samples were diluted 1:8 (TNF, IL-8) and 1 :20 (IL-6) in assay diluent prior to testing.
  • Carbon well B is composed of 5%> adsorbent 5 and demonstrated good adso ⁇ tion ability both in the well form and carbonised powder form, with significant removal of all three cytokines compared to the control.
  • Carbon wells C and D are composed of adsorbent 9 (80 and 100%) respectively) which also demonstrated good adso ⁇ tion capacity in the carbonised powder form.
  • Their superior adso ⁇ tion capacity compared to well B may be explained by their higher percentage mesoporous component.
  • Figures 12, 12A and 12B demonstrate the control of the macropore structure of the sintered resin derived carbons.
  • Figure 12 shows the relationship between the particle size of the resin used to produce the carbon and the macro pore size determined by mercury porosimetry of the finished carbon. It can be seen that there is a direct linear relationship with the mean pore size approximately 20% of the resin particle size. This is the relationship that would be expected from approximately close packed particles as shown in the diagram in figure 12 A.
  • Figure 12B shows the liquid phase filtration efficiency of these materials using a British Standard water based particulate challenge. It can be seen that the particulate removal efficiency is related to the particle size of the material used to produce the carbon. The cut of efficiency is actually considerably better than might be expected from the pore size of the material reflected in the data in figure 12 A.
  • Resin tubes were produced from cured 30 micron resin powders produced according to EP 0 254 551 , and the extrusion method described PCT/GB02/01142. These were then cured at 150C overnight. After drying the tubes were placed in a spray device that rotated the tubes at a fixed rate whilst moving the spray head along the tube.
  • the coating solution comprised a solution of partially cured novolak resin in ethylene glycol, prepared according to WO 02/12380 A2, and further diluted with isopropyl alcohol to give a viscosity suitable for spraying.
  • the tubes were then sprayed in two stages with an intermediate drying and curing step at 120C between the coating steps.
  • the operation is based on the initial separation of the blood into a plasma permeate stream and a cell enriched retentate stream.
  • the contrary substances are then adsorbed from the plasma stream as it permeates through the membrane structure (see figure 1 and 2). It is not necessary in this system that total removal of the blood cells occurs, as both streams are recombined before being passed back into the body. The requirement is to remove sufficient cells to allow effective adso ⁇ tion of the contrary molecules from the plasma during permeation. However it is also then essential that degradation of these blood cells does not occur during permeation.
  • the blood filtration tests were carried out using a tubular membrane system as shown in figure 1. This was sealed into a Perspex holder with feed, retentate and permeate connections. The feed flow and the pressure in the feed and permeate side of the membrane could be controlled separately whilst the retentate and permeate streams could be collected and analysed.
  • the red blood cell concentration was determined in the feed and permeate streams respectively. A reduction in the permeate cell concentration does not confirm conclusively that the cells have been removed as they could be destroyed during passage through the filter. However if this happens haemoglobin is released that can then be detected either directly by assay or by centrifugation of the permeate to remove the blood cells. If there was haemoglobin present due to cell destruction the filtrate after centrifugation would be pink.
  • the tubes evaluated are summarised below and comprise plain microporous resin based tubes (E789 to E840) based on 40 micron resin, binary tubes produced from either 9 micron (E786) or 40micron resin (E788/2) with 20% added mesoporous carbon and asymmetric spray coated tubes based on 30 micron resin.
  • the haemocrit concentration in the blood, retentate and filtrate is shown in figure 13 a. It can be seen that the levels of blood cells passing through the membrane is quite variable but for several of the tubes there are essentially no blood cells in the permeate. However comparison with figure 13 b, which shows the levels of haemoglobin in the feed and permeate streams shows that in most of these cases this was associated with extensive cell degradation.
  • the only sample that showed a good combination of trans membrane flux, blood cell removal and no cell degradation was 120205 which was an asymmetric structure with a spray coated membrane layer in contact with the blood, whilst the 10 micron resin carbon powder binary tubes showed good fluxes and some cell degradation.
  • the enhanced permeability relative to the 40 micron powder based tubes can be attributed to defects in the structure introduced by the active carbon powder.
  • the very low flows found with the 40 micron resin systems can probably be attributed to the use of unclassified powders where the smaller particles partially infill the voids between the larger particles resulting in reduced porosity and increased tortuosity.
  • the extensive cell degradation may then be due to the higher turbulence encountered in this more tortuous pathway.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • External Artificial Organs (AREA)

Abstract

L'invention concerne un appareil et un procédé pour supprimer les endotoxines et les exotoxines contenues dans le sang. Le procédé selon l'invention consiste à faire passer le sang d'un patient dans une structure carbonée monolithique poreuse pour former un flux filtrat et un flux retentat, et à combiner ces flux pour les réinjecter dans le patient.
PCT/GB2005/001501 2004-04-16 2005-04-18 Traitement de la sepsie WO2005099789A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0408521.3 2004-04-16
GBGB0408521.3A GB0408521D0 (en) 2004-04-16 2004-04-16 Treatment of sepsis

Publications (1)

Publication Number Publication Date
WO2005099789A1 true WO2005099789A1 (fr) 2005-10-27

Family

ID=32320953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/001501 WO2005099789A1 (fr) 2004-04-16 2005-04-18 Traitement de la sepsie

Country Status (2)

Country Link
GB (1) GB0408521D0 (fr)
WO (1) WO2005099789A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011070363A1 (fr) 2009-12-09 2011-06-16 Mast Carbon International Ltd Le charbon et son utilisation dans des applications de nettoyage du sang
US8815183B2 (en) 2009-08-31 2014-08-26 Corning Incorporated Zoned monolithic reactor and associated methods
US20190105631A1 (en) * 2016-03-31 2019-04-11 ImMutriX Therapeutics, Inc. Method for extracorporeal treatment of preeclampsia and related disorders
EA036052B1 (ru) * 2019-04-28 2020-09-21 Товарищество С Ограниченной Ответственностью "Научный Производственно-Технический Центр "Жалын" (Тоо "Научный Производственно-Технический Центр "Жалын") Устройство для перфузионной детоксикации крови

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254551A1 (fr) * 1986-07-22 1988-01-27 The British Petroleum Company P.L.C. Procédé pour la production d'articles conformés poreux
EP0467735A1 (fr) * 1990-07-03 1992-01-22 Alcoa Separations Technology Inc. Séparations de pyrogènes par ultrafiltration avec une céramique
DE19549420A1 (de) * 1995-04-27 1997-09-18 Braun Melsungen Ag Verfahren zur simultanen extrakorporalen Elimination von Tumor-Nekrose Faktor alpha (TNF alpha) und bakteriellen Lipopolysacchariden (LPS) aus Vollblut oder/und Blutplasma
US5750026A (en) * 1995-06-02 1998-05-12 Corning Incorporated Device for removal of contaminants from fluid streams
EP0958839A2 (fr) * 1996-02-06 1999-11-24 BELLCO S.p.A. Dispositif de séparation de toxines en particulier de cytokines
WO2002072240A2 (fr) * 2001-03-13 2002-09-19 Carbon Technologies Nv Procede et equipement permettant d'eliminer des composes volatils de l'air

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254551A1 (fr) * 1986-07-22 1988-01-27 The British Petroleum Company P.L.C. Procédé pour la production d'articles conformés poreux
EP0467735A1 (fr) * 1990-07-03 1992-01-22 Alcoa Separations Technology Inc. Séparations de pyrogènes par ultrafiltration avec une céramique
DE19549420A1 (de) * 1995-04-27 1997-09-18 Braun Melsungen Ag Verfahren zur simultanen extrakorporalen Elimination von Tumor-Nekrose Faktor alpha (TNF alpha) und bakteriellen Lipopolysacchariden (LPS) aus Vollblut oder/und Blutplasma
US5750026A (en) * 1995-06-02 1998-05-12 Corning Incorporated Device for removal of contaminants from fluid streams
EP0958839A2 (fr) * 1996-02-06 1999-11-24 BELLCO S.p.A. Dispositif de séparation de toxines en particulier de cytokines
WO2002072240A2 (fr) * 2001-03-13 2002-09-19 Carbon Technologies Nv Procede et equipement permettant d'eliminer des composes volatils de l'air

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815183B2 (en) 2009-08-31 2014-08-26 Corning Incorporated Zoned monolithic reactor and associated methods
WO2011070363A1 (fr) 2009-12-09 2011-06-16 Mast Carbon International Ltd Le charbon et son utilisation dans des applications de nettoyage du sang
EP2985046A1 (fr) * 2009-12-09 2016-02-17 ImmutriX Therapeutics, Inc. Le charbon et son utilisation dans des applications de nettoyage du sang
US9278170B2 (en) 2009-12-09 2016-03-08 Immuntrix Therapeutics, Inc. Carbon and its use in blood cleansing applications
US20190105631A1 (en) * 2016-03-31 2019-04-11 ImMutriX Therapeutics, Inc. Method for extracorporeal treatment of preeclampsia and related disorders
EA036052B1 (ru) * 2019-04-28 2020-09-21 Товарищество С Ограниченной Ответственностью "Научный Производственно-Технический Центр "Жалын" (Тоо "Научный Производственно-Технический Центр "Жалын") Устройство для перфузионной детоксикации крови

Also Published As

Publication number Publication date
GB0408521D0 (en) 2004-05-19

Similar Documents

Publication Publication Date Title
CN106178161B (zh) 使用固定于表面的多糖从血液中去除细胞因子的方法
US9278170B2 (en) Carbon and its use in blood cleansing applications
Clark et al. Extracorporeal sorbent technologies: basic concepts and clinical application
JP2013518687A5 (fr)
US10967115B2 (en) Toxin separator
US20240066470A1 (en) Filtration media
Bacal et al. Blood apheresis technologies–a critical review on challenges towards efficient blood separation and treatment
US20220105454A1 (en) Blood purifier
WO2005099789A1 (fr) Traitement de la sepsie
JP4997770B2 (ja) 吸着器
JP5017996B2 (ja) 白血球およびサイトカインの吸着器
US20210030942A1 (en) Devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood
JP5875779B2 (ja) 多孔質粒子、多孔質粒子の製造方法及び担体
JP5227271B2 (ja) 血液からウイルス及びサイトカインを除去するシステム
JP5722098B2 (ja) 多孔質粒子、多孔質粒子の製造方法及び担体
Karoor et al. Immunoaffinity removal of xenoreactive antibodies using modified dialysis or microfiltration membranes
Haase et al. The effect of three different miniaturized blood purification devices on plasma cytokine concentration in an ex vivo model of endotoxinemia
US20220111133A1 (en) Blood purifier
Damianaki et al. Expanding the potential therapeutic options of hemoperfusion in the era of improved sorbent biocompatibility
Xanthi et al. Use of therapeutical apheresis methods in ICU
Davankov et al. Hypercrosslinked Polystyrene as Hemosorbents
Pişkin Characterization of membranes for artificial organs
JP2568846C (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase